Comprehensive Age-Related Macular Degeneration Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Age-Related Macular Degeneration Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of age-related macular degeneration has been on a robust growth trajectory in the past few years. The market is expected to expand from a size of $9.96 billion in 2024 and reach a value of $10.7 billion come 2025, growing at a compound annual growth rate (CAGR) of 7.5%. The increase during the historical phase can be credited to the aging population, shifts in lifestyle and environmental triggers, genetic susceptibility, as well as raised awareness and early detection facilitated by advances in diagnostic methods.

Age-Related Macular Degeneration Market Size Forecast: What's the Projected Valuation by 2029?
The market for age-related macular degeneration is projected to experience robust augmentation over the next several years. It is moving towards hitting the "$14.38 billion mark by 2029, with a compound annual growth rate (CAGR) of 7.7%. The expansion during this forecast period is primarily due to advancements in genetics and biomarker research, developing therapeutic models, evolution of telemedicine and remote monitoring, as well as patient education and advocacy. The forecast period also indicates major trends such as implementation of personalized medicine techniques, advancements in retinal imaging technology, the introduction of durable drug delivery systems, clinical tests for experimental therapies, and partnerships for research and development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

What Are the Drivers Transforming the Age-Related Macular Degeneration Market?
The age-related macular degeneration (AMD) market is anticipated to grow, propelled by the increasing prevalence of AMD. AMD is an eye condition that progressively affects the macula, a tiny portion of the retina that plays a significant role in our central vision. Treatments for AMD aid patients with retinal disorders by reducing the severity of their ailment. For example, reports from Optimaxa., a UK-based laser eye treatment specialist, stated in February 2023 that globally, 196 million individuals were affected by AMD. This number is projected to rise to 288 million by 2040, representing 8.7% of the global population. Consequently, the escalating prevalence of AMD is fuelling the growth of the AMD market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp

What Long-Term Trends Will Define the Future of the Age-Related Macular Degeneration Market?
Leading companies in the age-related macular degeneration (AMD) market are ushering in novel therapies like bispecific antibodies to lower the frequency of treatments. Bispecific antibodies, designed to latch onto two distinct antigens at once, are at the forefront of these innovations. For instance, in May 2022, Vabysmo intravitreal injection 120 mg/mL, a bispecific antibody intended for the treatment of eye disorders such as AMD and diabetic macular edema (DME), was introduced by Japan's Chugai Pharmaceutical Co., Ltd. This trailblazing treatment works by simultaneously targeting two vital pathways: angiopoietin-2 (Ang-2) which is linked to aberrant growth of blood vessels and inflammation and Vascular Endothelial Growth Factor-A (VEGF-A) that plays a pivotal role in the creation of new blood vessels leading to vision impairment. One of the striking advantages of Vabysmo is its long administration intervals, allowing for treatments once every 16 weeks, thereby boosting patient comfort and compliance. Its two-pronged approach signifies a major breakthrough in eye treatments, successfully tackling the pressing demand for dependable therapies for retinal diseases.

Which Segments in the Age-Related Macular Degeneration Market Offer the Most Profit Potential?
The age-related macular degeneration market covered in this report is segmented -

1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy

Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional s, Low Vision Aids, Therapies For Geographic Atrophy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp

Which Firms Dominate the Age-Related Macular Degeneration Market by Market Share and Revenue in 2025?
Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

Which Regions Offer the Highest Growth Potential in the Age-Related Macular Degeneration Market?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10845

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.